Abstract
T cells must be activated before they can elicit damage to allografts, through interaction of their T cell receptor (TCR) with peptide-MHC complex, and through accessory molecules.
Signalling through accessory molecules or costimulatory molecules is a critical way for the immune system to fine tune T cell activation. An emerging therapeutic strategy is to target selective molecules involved in the process of T cell activation using biological agents, which do not impact TCR signalling, thus only manipulating the T cells which recognise alloantigen. Costimulatory receptors and their ligands are attractive targets for this strategy and could be used both to prevent acute graft rejection as well as for maintenance immunosuppression.
Therapeutic agents targeting costimulatory molecules, notably belatacept, have made the progression from the bench, through non-human primate studies and into the clinic. This Overview describes some of the most common costimulatory molecules, their role in T cell activation, and the development of reagents which target these pathways and their efficacy in transplantation.
T cell activation: a potential target for therapeutic blockade
T cells play a central role in the immune response towards an allograft (1) therefore interfering with the process of T cell activation has the potential of prolonging allograft survival through modulation of the alloresponse. Naïve CD4 + and CD8 + T cells must become activated in order to acquire effector functions which can result in graft damage (2) .
Activation of a naïve T cell is a tightly regulated process which requires three distinct signals.
Signal 1 determines the specificity of the immune response and involves the interaction between a given T cell receptor (TCR) on a T cell and a MHC-peptide complex on antigen presenting cells (APC) which generates a signal that is transmitted through the adjacent CD3
complex (3, 4) . Additional, so-called second signals are generated through other cell surface molecular interactions, known as costimulation (5) . The third signal is delivered from an APC to the T cell by means of cytokines. A number of cytokines have been implicated as providing signal 3, including IL-12 as it is able to promote Th1 differentiation (6) .
The accumulation and integration of intracellular signalling molecules from these 3 pathways triggers T cell gene transcription including IL-2, anti-apoptotic molecules, such as Bcl-2, molecules. Together such signals lead to clonal expansion and survival of antigen-specific T cells and influence the effector functions acquired by T cells as they differentiate, such as granzyme B a molecule that plays a role in the function of cytotoxic T cells (CTL or Tc).
Without costimulatory signals during the activation process, T cells become anergic and refractory to further stimulation by antigen (7) . Therefore targeting costimulatory pathways in the setting of transplantation has the potential to alter the evolution of an immune response to an allograft and prevent rejection. Figure 1 shows examples of costimulation pathways involved in the T cell response.
Costimulation
Although different costimulatory molecules can have over-lapping functions, which molecules act to co-stimulate T cell responses appears to depend on the stage of differentiation of the responding T cell as well as the availability of corresponding ligands (Table 1 ) (8) . This feature highlights the high degree of redundancy which has evolved to enable effective regulation of an immune response. Given the significant role played by costimulation in T cell activation, costimulation blockade provides a promising adjunctive or alternative therapy to the currently licenced immunosuppressive drugs used to prevent graft rejection.
Diversity of costimulatory molecules
Costimulatory molecules can be categorized by both their functional properties and structure.
Based on functionality, costimulatory molecules can be divided into those participating in positive costimulatory pathways promoting T cell activation, survival and/or differentiation, or negative costimulatory pathways which antagonise signals from the TCR resulting in suppression of T cell activation and termination of the immune response. Classification by structure divides costimulatory molecules into four distinct groups: (1) immunoglobulin (Ig) superfamily members (e.g. CD28); (2) tumour necrosis factor receptor (TNFR) family members (e.g. CD40); (3) cell adhesion molecules or integrins (e.g. LFA-1); T cell Ig domain and mucin domain (TIM) molecules. Figure 2 and Table 1 shows a number of the best characterized costimulatory molecules in the Ig and TNFR superfamilies. These two families will be the focus of this Overview, but it is important to note that this is not a definitive list of receptor-ligand pairs able to provide costimulation.
Therapeutic strategies in experimental models of transplantation
Novel immunosuppressive drugs and strategies are required for the prevention of allograft rejection to reduce the side effects associated with current immunosuppressive drug therapeutic regimens and to provide better control of the low grade immune response that leads to late allograft loss. A number of new agents have been developed which target immunological pathways in rejection for example; 1) modulation of cell surface molecules such as costimulatory molecules 2) inhibition of signalling cascades 3) inhibition of T cell proliferation and 4) modulation of cell trafficking. There are many different reagents being developed to target these pathways (9) , and this Overview will focus on the development of agents which impact the costimulatory pathways described above.
CD28/CTLA4:CD80/CD86 pathway
The CD28-CD80/CD86 axis was the first costimulatory pathway to be defined and is therefore the best characterised to date (10) (11) (12) (Table 1 ; (13, 14) ). After T cell activation, another receptor for CD80/CD86 is upregulated; CTLA4 (CD152) which although structurally homologous to CD28, has a ~20 fold higher affinity for CD80/CD86 and thus can out-compete CD28 for CD80/86 binding (Table 1 ; (15)). The CD28/CTLA4;CD80/CD86
axis has a dual function in the T cell response (Figure 3 (Figure 3 ). These data provide a rationale for combination therapies within the clinical setting.
CD40:CD154 pathway
The role of the CD40:CD154 pathway in immunity became clear when hyper-IgM syndrome was found to be a direct result of a mutation in the gene encoding CD154 (30). The effects of CD40 on the immune response are mediated by a signalling cascade which is initiated when it binds its ligand CD154 (CD40L) ( Table 1 ; (31, 32)); a CD28 independent event (33).
Initial efforts were aimed at blocking the CD40:CD154 interaction by use of monoclonal antibodies specific for CD154; an approach that showed promise in transplantation models in rodents (34-36) and in non-human primates (NHP) (37-39). Anti-CD154 has a preferential impact on effector T cells by inhibiting their activation and therefore proliferation, while also enriching the Treg population (40).
In preclincal studies it was found that rhesus monkeys given anti-CD154 mAb for 5 months as part of an induction therapy followed by 5 further monthly doses accepted kidney allografts for over a year after treatment was discontinued. However, the allografts were eventually rejected suggesting that tolerance was not achieved (38, 39). In addition, anti-CD154 (IDEC-131) alone significantly prolonged cardiac allograft survival in cynomolgus monkeys, while graft survival was further extended with the introduction of anti-thymocyte globulin in addition to anti-CD154 but as in previous studies did not induce tolerance (41).
More recently, reagents which target CD40 rather than CD154 have been developed. Anti- 
ICOS:ICOSL pathway
Another member of Ig superfamily is inducible costimulator (ICOS; CD278) ( Table 1; blockade is going to reach its full therapeutic potential.
PD-1:PD-L1/L2 pathway
Like CTLA-4, PD-1 (CD279) is also a member of the Ig superfamily that has co-inhibitory activity (Table 1 ; (52) 
OX40:OX40L pathway
The TNFR superfamily member OX40 (CD134) is transiently induced on both CD4 + (57) and CD8 + (58) T cells after activation (Table 1) which is involved in the late expansion phase of effector T cells, as well as promoting memory T cell generation (59, 60) . Blocking the OX40-OX40L pathway (using an OX40-Ig fusion protein) in a mouse model of cardiac transplantation was found to result in prolonged cardiac allograft survival when donor and recipient were mismatched at a minor histocompatibility antigen loci but not across a full MHC mismatch (61) . In contrast, in a full-MHC mismatch model where TCR transgenic CD8 + T cells were adoptively transferred into syngeneic T cell deficient recipients, anti-OX40 was able to significantly prolong skin graft survival, although tolerance was not achieved (62) . OX40:OX40L has been suggested to be utilised differentially by effector and regulatory T cells (Treg). For example, blockade of OX40:OX40L inhibits the generation of an optimal effector T cell pool by promoting activation induced cell death (59, 62) , whilst concomitantly aiding the induction of Treg (63, 64) . These data provide a clear precedent for the utilisation of OX40-OX40L blockade in transplantation however this appears to be contingent on suboptimal or low frequency T cell responses.
41BB:41BBL pathway
Another inducible costimulatory molecule in the TNFR superfamily is 4-1BB (CD137), and ligation of 4-1BB to its ligand (41BBL) ( 
CD27:CD70 pathway
The final TNFR family member to be discussed in this review is CD27 and its interaction with ligand CD70 (Table 1 ; (70) . CD70 expression is dependent on TCR stimulation and TLR stimulation (71) . The CD27-CD70 interaction has been implicated in T cell development, T cell activation and T cell dependent antibody production by B cells (72) .
Blockade of CD27-CD70 pathway prolongs allograft survival in fully MHC mismatched cardiac allografts in wild type recipients (73) . But in CD28 
Obstacles to tolerance induction and clinical translation
There is a growing body of evidence in rodent models to suggest that blocking costimulation can lead to tolerance induction (35, 85), however, data from NHP studies is more complex, and suggests that tolerance induction is more difficult to achieve in higher animals including humans (37-39, 86). These differences can be explained in part by the increased complexity of the higher vertebrate immune system and the increased diversity of pre-existing immunity due to exposure to environmental antigens (87). Although outbred laboratory animals have a wider diversity of exposure to such antigens, they are still less immunologically educated compared to humans. Differences can also result due to basic observations such as size;
vastly different number of total cells able to respond as well as differences in drug absorption and clearance. Despite these differences, large animal models remain the best way to gain knowledge before initiating a safe and ethically robust clinical trial.
The leap from bench-side to bedside
Targeting costimulatory molecules has great potential in transplantation for preventing rejection as the therapy will only impact T cells undergoing activation. As a result the specificity of immunosuppression achieved using this therapeutic approach has the potential to be increased compared to current small molecule immunosuppressive drugs. 
Future opportunities
The 
